Humasis Co

Humasis Co Pre-Tax Margin

The Pre-Tax Profit Margin of Humasis Co (205470.KQ) as of Oct 27, 2026 is -70.72 %. In the previous year, Pre-Tax Profit Margin was -148.06 % — a change of -52.24% (higher).

Pre-Tax Margin

-70.72 %

YoY

-52.24%

Last updated:

Pre-Tax Profit Margin of Humasis Co is 2025 -70.72 % . Pre-Tax Profit Margin of Humasis Co was 2024 -148.06 % . It decreases by -52.24% higher compared to the previous year.

The Humasis Co Pre-Tax Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Pre-Tax Margin
Date
Pre-Tax Margin
Jan 1, 2018
-8.83 KRW
Jan 1, 2019
-13.40 KRW
Jan 1, 2020
46.17 KRW
Jan 1, 2021
61.13 KRW
Jan 1, 2022
50.41 KRW
Jan 1, 2023
-449.69 KRW
Jan 1, 2024
-148.06 KRW
Jan 1, 2025
-70.72 KRW
The Humasis Co Pre-Tax Margin history
YEARPre-Tax MarginYoY
-70.72 %-52.24%
-148.06 %-67.07%
-449.69 %-992.11%
50.41 %-17.54%
61.13 %+32.40%
46.17 %-444.54%
-13.40 %+51.76%
-8.83 %-75.60%
-36.19 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Humasis Co Stock analysis

What does Humasis Co do? Humasis Co., Ltd. develops rapid test kits and point-of-care testing instruments for the domestic and overseas markets. The company manufactures immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, and cancer marker test devices. It also researches and develops biomaterials. Humasis sells its products to customers in South Korea and international markets, focusing on healthcare providers and medical institutions that require diagnostic tools for diseases like heart attacks, infections, and cancer. The company's revenue comes from the sale of its diagnostic devices and biomaterials research. Products include immunoquantitative analysis devices, myocardial infarction test equipment, and cancer marker test devices. These are sold to healthcare providers and medical institutions in South Korea and overseas. Humasis targets segments in the medical diagnostics field, particularly for cardiovascular, infectious disease, and oncology applications. Humasis Co., Ltd. operates in the medical device sector, focusing on point-of-care testing solutions. Its product portfolio includes devices for myocardial infarction, infectious diseases, hormones, and cancer markers. The company's sales are driven by demand from hospitals and clinics that need rapid diagnostic tools for patient care. The firm's research and development in biomaterials supports its product offerings in the medical diagnostics market. Humasis Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humasis Co stock

Pre-Tax Profit Margin of Humasis Co is -70.72 % in 2025.

Pre-Tax Profit Margin of Humasis Co changed from -148.06 % to -70.72 %, representing a -52.24% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Pre-Tax Profit Margin Humasis Co since 2006 – with annual values, charts, and detailed analysis.

Pre-tax margin measures the percentage of revenue remaining after all expenses except income taxes. It isolates operational and financial performance from tax effects.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Pre-Tax Profit Margin's Humasis Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Pre-Tax Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Pre-Tax Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Humasis Co

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Humasis Co